| アブストラクト | American Urological Association (AUA) guidelines recommend selective serotonin reuptake inhibitors (SSRI) as first-line pharmacotherapy for premature ejaculation (PE). While previous studies have described sexual adverse events (AE) associated with each medication, there is limited data directly comparing rates of specific sexual AEs across SSRIs. This study investigates the Food and Drug Administration Adverse Event Reporting System (FAERS) database for reports of monotherapy use of fluoxetine 20 mg, paroxetine 20 mg, sertraline 50 mg, and sertraline 100 mg in males from January 2004-June 2021. We examined 2608 reports from patients using SSRIs for PE or other psychiatric conditions. The average number of AEs was significantly different (p < 0.01) with paroxetine 20 mg having the highest (5.1 AEs/case report). Changes in libido was the most common sexual AE for fluoxetine 20 mg (6.7% of reports), paroxetine 20 mg (4.2%), and sertraline 50 mg (7.2%) while orgasm disorder was the most reported for sertraline 100 mg (3.9%). The SSRIs had different rates of changes in libido, erection disorder, orgasm disorder, and other sexual dysfunction (outside those listed). The SSRIs also differed in the rates of fatigue, ear/hearing changes, headache, and psychological AEs. The differences in specific AEs warrant future studies to determine true differences that would affect patient counseling. |
|---|
| ジャーナル名 | International journal of impotence research |
|---|
| Pubmed追加日 | 2023/2/23 |
|---|
| 投稿者 | Tram, Michael; Meyerson, Brian; Welliver, Charles; Inouye, Brian |
|---|
| 組織名 | Department of Urology, Albany Medical Center, Albany, NY, USA. tramm@amc.edu.;Department of Urology, Albany Medical Center, Albany, NY, USA.;Albany Stratton Veterans Affairs Medical Center, Albany, NY, USA. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/36806781/ |
|---|
